ArticleJournal of nanobiotechnology2026
Magnetic field-controlled nanozymes effectively overcome therapeutic limitations in tumor ferroptosis therapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Iron oxide nanozymes with intrinsic peroxidase-like activity and excellent biosafety are considered ideal agents for inducing tumor ferroptosis. However, their practical catalytic efficiency is often constrained by an inherent delocalized electronic structure and the restrictive tumor antioxidant microenvironment. Herein, we report a magnetic field-mediated strategy to synthesize ultra-small superparamagnetic manganese-doped iron oxide (USMIO) nanoparticles with precisely tailored multi-enzyme activities (denoted as MUSMIO). The magnetic field in situ generated abundant oxygen vacancies and optimized the Mn/Fe coordination environment, significantly boosting electron transfer and catalytic performance. MUSMIO exhibited robust pH-responsive peroxidase-like activity with a hydroxyl radical yield ∼5.86-fold higher than pure ultra-small superparamagnetic iron oxide (USIO) and ∼2.43-fold higher than USMIO, together with favorable catalase-, glutathione oxidase-, and nicotinamide adenine dinucleotide phosphate oxidase-like activities. This synergistic multi-enzyme cascade efficiently blocked glutathione regeneration, relieved tumor hypoxia, and triggered a sustained hydroxyl radical storm to drive extensive lipid peroxidation and selective ferroptosis in cancer cells, while exhibiting negligible toxicity to normal cells. In a murine breast cancer model, MUSMIO achieved complete tumor regression with no recurrence, and prolonged the median survival time of mice with excellent biosafety. This work provides a generalizable physical-field-assisted route for designing high-performance multi-enzyme mimetic nanozymes for targeted tumor therapy.
Indexed as
Identifiers
42919272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.